An increasing percentage of people have or are at risk to develop non-alcoholic fatty liver
disease (NAFLD) worldwide. NAFLD comprises different stadia going from isolated steatosis …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide, and scientific studies consistently report that NAFLD development can be …

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents
with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes …

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different
entities sharing common clinical and physio-pathological features, with insulin resistance …

Modifications in the microbiota caused by environmental and genetic reasons can
unbalance the intestinal homeostasis, deregulating the host's metabolism and immune …

Background Lipid accumulation product (LAP) is an index calculated by waist circumference
(WC) and triglyceride (TG), which reflects lipid toxicity. This study aims to investigate the …

The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still
facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival …

Background Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel
disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux …

Background: With no approved pharmacotherapy to date, the present therapeutic
cornerstone for non-alcoholic fatty liver diseases (NAFLD) is a lifestyle intervention …

Abstract Background & Aims Following the classification of metabolic dysfunction‐
associated fatty liver disease (MAFLD), non‐alcoholic fatty liver disease (NAFLD) has …